Condition: Colorectal Cancer · Advanced Adenocarcinoma · Sponsor: Universal Diagnostics
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
This description comes directly from the study's public registry record.
Kara Mattox · (+1)3392085320 · kara.mattox@universaldx.com
Always discuss trial participation with your own doctor first.
| Gastroenterology Consultants of SW Virginia | Raonoke, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06059963